<DOC>
	<DOCNO>NCT01375751</DOCNO>
	<brief_summary>The primary objective study evaluate effect 12 week subcutaneous evolocumab ( AMG 145 ) , compare placebo , percent change baseline LDL-C adult heterozygous familial hypercholesterolemia ( HeFH ) .</brief_summary>
	<brief_title>Reduction Low-Density Lipoprotein Cholesterol ( LDL-C ) With PCSK9 Inhibition Heterozygous Familial Hypercholesterolemia Disorder Study</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Male female ≥ 18 ≤ 75 year age Diagnosis heterozygous familial hypercholesterolemia meet diagnostic criterion outline Simon Broome Register Group ( Scientific Steering Committee 1991 ) On approve statin , without ezetimibe , stable dose ( ) least 4 week Fasting LowDensity Lipoprotein Cholesterol ( LDLC ) ≥ 100 mg/dL Fasting triglycerides ≤ 400 mg/dL Homozygous familial hypercholesterolemia LowDensity Lipoprotein ( LDL ) plasma apheresis within 12 month prior randomization New York Heart Association ( NYHA ) III IV heart failure , know leave ventricular ejection fraction &lt; 30 % Uncontrolled cardiac arrhythmia Myocardial infarction , unstable angina , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) stroke within 3 month prior randomization Type 1 diabetes ; newly diagnose poorly control type 2 diabetes ( HbA1c &gt; 8.5 % ) Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
	<keyword>Proprotein convertase subtilisin/kexin type 9 ( PCSK9 )</keyword>
</DOC>